| 12319671 |
1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof |
Hua Zhou, John J. Acton, III, Michael J. Ardolino, Yi-Heng Chen, Peter H. Fuller +15 more |
2025-06-03 |
|
| 12157727 |
Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
Yongxin Han, Yongqi Deng, Hua Zhou, Meredeth A. McGowan, Hongjun Zhang +3 more |
2024-12-03 |
$1,481,364,000 |
| 11498904 |
Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
Yongxin Han, Abdelghani Achab, Indu T. Bharathan, Xavier Fradera, Derun Li +1 more |
2022-11-15 |
$883,400,000 |
| 11319295 |
Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
Catherine White, Meredeth A. McGowan, Yongxin Han |
2022-05-03 |
$363,616,000 |
| 11319283 |
Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
Meredeth A. McGowan, Abdelghani Achab, Xavier Fradera, Yongxin Han, Derun Li +6 more |
2022-05-03 |
$363,616,000 |
| 11208407 |
Substituted phenyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
Hua Zhou, Abdelghani Achab, Xavier Fradera, Yongxin Han, Derun Li +3 more |
2021-12-28 |
$153,354,000 |
| 11111232 |
Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
Catherine White, Abdelghani Achab, Indu T. Bharathan, Xavier Fradera, Yongxin Han +7 more |
2021-09-07 |
$168,031,000 |
| 11103493 |
Substituted pyridinyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
Hua Zhou, Xavier Fradera, Yongxin Han, Meredeth A. McGowan, Catherine White +1 more |
2021-08-31 |
$154,425,000 |
| 10995085 |
Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
Yongxin Han, Abdelghani Achab, Yongqi Deng, Xavier Fradera, Craig R. Gibeau +8 more |
2021-05-04 |
$204,878,000 |
| 10745364 |
Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
Thomas D. Aicher, Chad A. VanHuis, William D. Thomas, John MacLean, Brian M. Andresen +9 more |
2020-08-18 |
$154,425,000 |
| 10647705 |
Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
Yongxin Han, Abdelghani Achab, Yongqi Deng, Xavier Fradera, Craig R. Gibeau +8 more |
2020-05-12 |
$155,382,000 |
| 10538497 |
Compounds as indoleamine 2,3-dioxygenase inhibitors |
Yongxin Han, Abdelghani Achab, Purakkattle Biju, Yongqi Deng, Xavier Fradera +9 more |
2020-01-21 |
$220,499,000 |
| 10508108 |
Tricyclic compounds as inhibitors of mutant IDH enzymes |
Christian Fischer, Stephane L. Bogen, Matthew L. Childers, Francesc Xavier Fradera Llinas, J. Michael Ellis +17 more |
2019-12-17 |
$237,534,000 |
| 10442819 |
Tricyclic compounds as inhibitors of mutant IDH enzymes |
Christian Fischer, Stephane L. Bogen, Matthew L. Childers, Francesc Xavier Fradera Llinas, J. Michael Ellis +28 more |
2019-10-15 |
$166,889,000 |
| 10221146 |
Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
Thomas D. Aicher, Chad A. VanHuis, William D. Thomas, John MacLean, Brian M. Andresen +9 more |
2019-03-05 |
$69,271,000 |
| 10221142 |
Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof |
Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Kun Liu, Benjamin Wesley Trotter +5 more |
2019-03-05 |
$69,271,000 |
| 10086000 |
Tricyclic compounds as inhibitors of mutant IDH enzymes |
Christian Fischer, Stephane L. Bogen, Matthew L. Childers, Francesc Xavier Fradera Llinas, Alexander Kim +9 more |
2018-10-02 |
$122,453,000 |
| 9809561 |
Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
Thomas D. Aicher, Chad A. VanHuis, William D. Thomas, John MacLean, Brian M. Andresen +9 more |
2017-11-07 |
$37,151,000 |
| 9783511 |
Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease |
Thomas D. Aicher, Chad A. VanHuis, John MacLean, Brian M. Andresen, Kenneth J. Barr +6 more |
2017-10-10 |
$124,275,000 |
| 9663522 |
3-aminocycloalkyl compounds as RORgammaT inhibitors and uses thereof |
Kenneth J. Barr, John MacLean, Hongjun Zhang, Richard Thomas Beresis, Neville J. Anthony +2 more |
2017-05-30 |
$63,958,000 |
| 9663502 |
2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease |
Thomas D. Aicher, Chad A. VanHuis, John MacLean, Brian M. Andresen, Kenneth J. Barr +9 more |
2017-05-30 |
$63,958,000 |
| 9556168 |
N-alkylated indole and indazole compounds as RORgammaT inhibitors and uses thereof |
Kenneth J. Barr, Corey E. Bienstock, John MacLean, Hongjun Zhang, Richard Thomas Beresis +2 more |
2017-01-31 |
$47,481,000 |
| 9487490 |
3-cyclohexenyl and cyclohexyl substituted indole and indazole compounds as RORgammaT inhibitors and uses thereof |
Kenneth J. Barr, John MacLean, Hongjun Zhang, Richard Thomas Beresis, Dongshan Zhang +3 more |
2016-11-08 |
$82,214,000 |
| 8685977 |
Chemical compounds |
Andrew Simon Bell, Alan Daniel Brown, Russell Andrew Lewthwaite, Ian Roger Marsh, David S. Millan +6 more |
2014-04-01 |
$235,129,000 |
| 8592629 |
Sulfonamide derivatives as Nav 1.7 inhibitors |
Andrew Simon Bell, Alan Daniel Brown, Marcel John De Groot, Russell Andrew Lewthwaite, Ian Roger Marsh +6 more |
2013-11-26 |
$220,822,000 |
